Format

Send to

Choose Destination
Appl Microbiol Biotechnol. 2015 Aug;99(16):6563-70. doi: 10.1007/s00253-015-6776-x. Epub 2015 Jul 4.

Probiotic Saccharomyces cerevisiae strains as biotherapeutic tools: is there room for improvement?

Author information

1
Laboratório de Dermatologia e Imunodeficiências, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.

Abstract

The probiotic yeast Saccharomyces cerevisiae var boulardii is widely used as a low cost and efficient adjuvant against gastrointestinal tract disorders such as inflammatory bowel disease and treatment of several types of diarrhea, both in humans and animals. S. boulardii exerts its protective mechanisms by binding and neutralizing enteric pathogens or their toxins, by reducing inflammation and by inducing the secretion of sIgA. Although several S. cerevisiae strains have proven probiotic potential in both humans and animals, only S. boulardii is currently licensed for use in humans. Recently, some researchers started using S. boulardii as heterologous protein expression systems. Combined with their probiotic activity, the use of these strains as prophylactic and therapeutic proteins carriers might result in a positive combined effort to fight specific diseases. Here, we provide an overview of the current use of S. cerevisiae strains as probiotics and their mechanisms of action. We also discuss their potential to produce molecules with biotherapeutic application and the advantages and hurdles of this approach. Finally, we suggest future directions and alternatives for which the combined effort of specific immunomodulatory effects of probiotic S. cerevisiae strains and ability to express desired foreign genes would find a practical application.

PMID:
26142388
DOI:
10.1007/s00253-015-6776-x
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center